HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression
HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression
复制标题
DOI：
10.1016/j.leukres.2006.09.017
复制
发表时间：
2007-07-01
影响因子：
2.7
通讯作者：
Hayashi, Yoshitake
中科院分区：
文献类型：
--
作者：
Syampurnawati, Mellam;Tatsumi, Eiji;Hayashi, Yoshitake
在29例DR阴性（DR-）M1/M2 AML样本中研究了FLT 3突变和细胞表面抗原，并与30例DR阳性（DR+）M1/M2 AML样本进行了比较。在59.3%的样本中检测到FLT 3-ITD，在7.4%的样本中检测到D835。DR-组FLT 3-ITD的发生率（59.3%）高于DR+组（17.9%; P = 0.002）。DR-状态与CD 34（-）相关（82.8%）。CD 7（-）（92.9%）和CD 45 RO（+）（76%）状态。我们的研究结果表明FLT 3突变是在DR-M1/M2 AML中发现的最常见的基因改变。这些结果对于进一步表征这种表型AML实体是重要的。(C)2006爱思唯尔有限公司保留所有权利。
FLT3 mutations and cell-surface antigen were investigated in 29 DR-negative (DR-) M1/M2 AML samples in comparison with 30 DR-positive (DR+) M1/M2 AML samples. FLT3-ITD was detected in 59.3% and D835 was detected in 7.4% of the samples. The incidence of FLT3-ITD was higher in the DR- group (59.3%) than in the DR+ group (17.9%; P = 0.002). The DR- status was associated with the CD34(-) (82.8%). CD7(-) (92.9%) and CD45RO(+) status (76%). Our results indicated that FLT3 mutation is the most common gene alteration found in the DR- M1/M2 AML. These results are important for further characterizing this phenotypic AML entity. (C) 2006 Elsevier Ltd. All rights reserved.